4.7 Article

Management and treatment of glomerular diseases (part 2): conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference

期刊

KIDNEY INTERNATIONAL
卷 95, 期 2, 页码 281-295

出版社

ELSEVIER SCIENCE INC
DOI: 10.1016/j.kint.2018.11.008

关键词

anti-neutrophil cytoplasmic antibody-associated vasculitis; C3 glomerulopathy; focal and segmental glomerulosclerosis; KDIGO; lupus nephritis; membranoproliferative glomerulonephritis; minimal change disease; monoclonal gammopathies of renal significance

资金

  1. KDIGO
  2. Achillion
  3. Aurinia Pharmaceuticals
  4. Calliditas Therapeutics
  5. ChemoCentryx
  6. Chugai
  7. Expedition Therapeutics
  8. Gilead
  9. Goldfinch Bio
  10. Kyowa Kirin
  11. Mallinckrodt Pharmaceuticals
  12. Novartis
  13. Omeros
  14. Sanofi Genzyme
  15. Vifor Fresenius Medical Care Renal Pharma

向作者/读者索取更多资源

In November 2017, the Kidney Disease: Improving Global Outcomes (KDIGO) initiative brought a diverse panel of experts in glomerular diseases together to discuss the 2012 KDIGO glomerulonephritis guideline in the context of new developments and insights that had occurred over the years since its publication. During this KDIGO Controversies Conference on Glomerular Diseases, the group examined data on disease pathogenesis, biomarkers, and treatments to identify areas of consensus and areas of controversy. This report summarizes the discussions on primary podocytopathies, lupus nephritis, anti-neutrophil cytoplasmic antibody-associated nephritis, complement-mediated kidney diseases, and monoclonal gammopathies of renal significance.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.7
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据